LG Chem Life Sciences
- United States
LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients
Seoul, South Korea & Cambridge, Mass., United States: LC350189 showed significant serum uric acid (sUA)-lowering effects across all dose levels.…
Read More » - Technology
LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States
Nanjing, China & Seoul, South Korea & Cambridge, Mass., United States: LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co.…
Read More » - Health
LG Chem to Contribute to Global Polio Eradication with Eupolio™, the First Sabin Inactivated Polio Vaccine to Receive WHO Prequalification
LG Chem Sabin-Inactivated Polio Vaccine (Sabin-IPV) Eupolio™ (Photo: Business Wire) Seoul, South Korea: LG Chem announced today that its Sabin-Inactivated…
Read More » - World
LG Chem Life Sciences and TransThera Biosciences Announce FDA Clearance of IND for TT-01025, a SSAO/VAP-1 Inhibitor
Nanjing, China & Seoul, Korea: LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co.…
Read More » - Business
LG Chem Life Sciences and TransThera Biosciences Announce License Agreement for Potential Treatment of NASH and Other Chronic Inflammatory Conditions
Nanjing, China & Seoul, South Korea: LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences…
Read More »